



Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ

Aliya A. Khan,^{*,1} Archie Morrison,² David L. Kendler,³ Rene Rizzoli,⁴ David A. Hanley,⁵ Dieter Felsenberg,⁶ Laurie K. McCauley,⁷ Felice O’Ryan,⁸ Ian R. Reid,⁹ Salvatore L. Ruggiero,^{10,11,12} Akira Taguchi,¹³ Sotirios Tetradis,¹⁴ Nelson B. Watts,¹⁵ Maria Luisa Brandi,¹⁶ Edmund Peters,¹⁷ Teresa Guise,¹⁸ Richard Eastell,¹⁹ Angela M. Cheung,^{20,21,22} Suzanne N. Morin,²³ Basel Masri,²⁴ Cyrus Cooper,^{25,26,27} Sarah L. Morgan,²⁸ Barbara Obermayer-Pietsch,²⁹ Bente L. Langdahl,³⁰ Rana Al Dabagh,³¹ K. Shawn Davison,³² George K. Sándor,³³ Robert G. Josse,³⁴ Mohit Bhandari,³⁵ Mohamed El Rabbany,³⁶ Dominique D. Pierroz,³⁷ Riad Sulimani,³⁸ Deborah P. Saunders,³⁹ Jacques P. Brown,⁴⁰ Juliet Compston⁴¹ on behalf of the International Task Force on Osteonecrosis of the Jaw

¹Department of Medicine, Divisions of Endocrinology and Metabolism and Geriatrics, McMaster University, Hamilton, ON, Canada; ²Division of Oral and Maxillofacial Surgery, Dalhousie University, Halifax, NS, Canada; ³Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada; ⁴Division of Bone Diseases, Geneva University Hospitals, Geneva, Switzerland; ⁵Departments of Medicine, Community Health Sciences and Oncology, University of Calgary, Calgary, AB, Canada; ⁶Centre of Muscle & Bone Research, Charité-University Medicine Berlin, Campus Benjamin Franklin, Free University & Humboldt University Berlin, Berlin, Germany; ⁷Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA; ⁸Division of Maxillofacial Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA; ⁹Department of Medicine, University of Auckland, Auckland, New Zealand; ¹⁰Division of Oral and Maxillofacial Surgery, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA; ¹¹Stony Brook School of Dental Medicine, Stony Brook, NY, USA; ¹²New York Center for Orthognathic and Maxillofacial Surgery, New York, NY, USA; ¹³Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, Shojiri, Japan; ¹⁴Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA; ¹⁵Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA; ¹⁶Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; ¹⁷Department of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; ¹⁸Department of Medicine, Division of Endocrinology at Indiana University, Indianapolis, IN, USA; ¹⁹Department of Human Metabolism, University of Sheffield, Sheffield, UK; ²⁰Department of Medicine, University of Toronto, Toronto,

Sponsoring Societies: American Society of Bone and Mineral Research, American Association of Oral and Maxillofacial Surgeons, Canadian Association of Oral and Maxillofacial Surgeons, Canadian Academy of Oral and Maxillofacial Pathology and Oral Medicine, European Calcified Tissue Society, International Bone and Mineral Society, International Society of Clinical Densitometry, International Osteoporosis Foundation, International Association of Oral and Maxillofacial Surgeons, International Society of Oral Oncology, Japanese Society for Bone and Mineral Research, Osteoporosis Canada, Pan Arab Osteoporosis Society, and The Endocrine Society.

*Address correspondence to: Aliya A. Khan, MD, FRCPC, FACP, FACE, Department of Medicine, Divisions of Endocrinology and Metabolism and Geriatrics, McMaster University, 223#3075 Hospital Gate, Oakville, Ontario L6M 1M1, Canada. E-mail: Aliya@mcmaster.ca

ON, Canada;²¹Centre of Excellence in Skeletal Health Assessment, Joint Department of Medical Imaging, University Health Network (UHN), Toronto, ON, Canada;²²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada;²³Department of Medicine, McGill University, Montreal, QC, Canada;²⁴Jordan Osteoporosis Center, Jordan Hospital & Medical Center, Amman, Jordan;²⁵MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK;²⁶NIHR Nutrition Biomedical Research Centre, University of Southampton, Southampton, UK;²⁷NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK;²⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham Osteoporosis Prevention and Treatment Clinic, Birmingham, AL, USA;²⁹Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University Graz, Graz, Austria;³⁰Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark;³¹Faculty of Dentistry, University of Toronto, Toronto, Canada;³²Department of Education, University of Victoria, Victoria, BC, Canada;³³Department of Oral and Maxillofacial Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland;³⁴Division of Endocrinology and Metabolism, University of Toronto, Toronto, ON, Canada;³⁵Division of Orthopaedic Surgery, Department of Surgery, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada;³⁶Faculty of Dentistry, University of Toronto, Toronto, ON, Canada;³⁷International Osteoporosis Foundation (IOF), Nyon, Switzerland;³⁸College of Medicine, King Saud University, Riyadh, Saudi Arabia;³⁹Department of Dental Oncology, Northeast Cancer Centre/Health Science North, Sudbury, ON, Canada;⁴⁰Rheumatology Division, CHU de Québec Research Centre, Laval University, Québec City, QC, Canada; and ⁴¹Department of Medicine, Cambridge Biomedical Campus, Cambridge, UK

Abstract

Osteonecrosis of the jaw (ONJ) has been associated with antiresorptive therapy in both oncology and osteoporosis patients. This debilitating condition is very rare and advances in diagnosis and management may now effectively reduce the risk of its development and offer valuable treatment options for affected patients. This paper provides a case-based review of ONJ and application of the International Task Force on ONJ (referred to as the “Task Force”) recommendations for the diagnosis and management of ONJ. The Task Force was supported by 14 international societies and achieved consensus from representatives of these multidisciplinary societies on key issues pertaining to the diagnosis and management of ONJ. The frequency of ONJ in oncology patients receiving oncology doses of bisphosphonate (BP) or denosumab is estimated at 1%–15%, and the frequency in the osteoporosis patient population receiving much lower doses of BP or denosumab is estimated at 0.001%–0.01%. Although the diagnosis of ONJ is primarily clinical, imaging may be helpful in confirming the diagnosis and staging. In those with multiple risk factors for ONJ for whom major invasive oral surgery is being planned, interruption of BP or denosumab therapy (in cancer patients) is advised, if possible, before surgery, until the surgical site heals. Major oral surgery in this context could include multiple extractions if surgical extractions are required, not simple forceps extractions. ONJ development may be reduced by optimizing oral hygiene and postoperatively using topical and systemic antibiotics as appropriate. Periodontal disease should be managed before starting oncology doses of BP or denosumab. Local debridement may be successful in disease unresponsive to conservative therapy. Successful surgical intervention has been reported in those with stage 3 disease; less severe disease is best managed conservatively. Teriparatide may be helpful in healing ONJ lesions and may be considered in osteoporosis patients at a high fracture risk in the absence of contraindications. Resumption of BP or denosumab therapy following healing of ONJ lesions is recommended, and there have not been reports of subsequent local recurrence.

Key Words: Bisphosphonates; denosumab; diagnosis; management; osteonecrosis of the jaw.

This paper provides an overview of osteonecrosis of the jaw (ONJ) diagnosis and management by The International Task Force on ONJ, composed of leading basic scientists and dental and medical experts. This review additionally provides physician and patient tools to assist in the management and understanding of ONJ and can be used in concert with the findings of other recently published international guidelines by the International Task Force on ONJ (1).

Nine key questions were identified that addressed areas germane to the diagnosis and management of ONJ. A search

strategy was developed that considered interventions, populations, areas of interest, and outcomes. Electronic searches were conducted for each of the questions for articles published between January 1, 2003, and March 1, 2016, indexed in PubMed or EMBASE databases. Pertinent literature identified in the searches was graded as to their quality of evidence, and topic experts provided relevant literature not captured in the searches.

A case-based discussion is provided to illustrate the findings of the International Task Force on ONJ.

Case

A 65-yr-old female presents with “jaw pain” in the osteoporosis clinic and has experienced a prior vertebral fracture with fall on ice at the age of 60 yr. The patient has been on alendronate 70 mg weekly for the past 7 yr and is now concerned that she may have ONJ as advised by her neighbor. She has a 15-yr history of type 2 diabetes mellitus and is on multidose insulin. Her HbA1C is 8.5%. She has polymyalgia rheumatic and has been on prednisone 5 mg daily for the past 3 yr. She smokes 1 pack of cigarettes per day and sees her dentist infrequently at most every few years.

The patient’s bone mineral density (BMD) was recently determined at the femoral neck to be 0.562 g/cm², corresponding to a *T*-score of −2.6.

Does She Have ONJ?

ONJ was first described more than a decade ago (2,3) and is defined as an area of exposed bone in the oral cavity that does not heal within 8 wk following identification by a healthcare provider in a patient who has been receiving or has been exposed to a bisphosphonate (BP) or denosumab therapy and has not had radiation therapy in the craniofacial region or evidence of local malignancy (4). The new American Association of Maxillofacial Surgeons (AAOMS) definition of ONJ also includes exposure to antiangiogenic agents (5). The diagnosis is confirmed clinically by a dentist or oral surgeon following exclusion of other conditions which can present with pain or local oral symptoms. Additional imaging may be required to clarify the diagnosis and to determine the stage of the condition if present.

Spontaneous oral ulceration with bone sequestration (OUBS) has also been described and shows some shared features with ONJ, although it occurs in the absence of antiresorptive medication. OUBS typically presents on the posterior lingual aspect of the mandible or in association with exostoses. The patient presents with a small ulceration and exposure of underlying nonvital cortical bone. Usually, the nonvital bone base will spontaneously sequester and then efficient healing ensues. Some of these cases can persist beyond 8 wk and the etiopathogenesis is not well understood (6–16). The incidence of OUBS in the general population is still not defined (17,18). This issue begs the question whether this represents a “nonmedication related” form of ONJ. This is still being debated.

Our patient will need to consult with her dentist and any referred dental specialist to confirm if she has ONJ.

If Present, What Is the Stage of Her ONJ?

Determining the stage of the ONJ lesion is helpful in establishing prognosis and the best management strategy (19–21). Patients with stage 1 disease have exposed bone and are asymptomatic without evidence of significant adjacent or regional soft tissue inflammation or infection. Stage

2 disease is characterized by exposed bone with associated pain, adjacent or regional soft tissue inflammatory swelling, or secondary infection. Stage 3 disease is characterized by exposed bone associated with pain, adjacent or regional soft tissue inflammatory swelling, or secondary infection in addition to a pathological fracture, an extraoral fistula or oral antral fistula, or radiographic evidence of osteolysis extending to the inferior border of the mandible or the floor of the maxillary sinus (see Fig. 1—stages 1–3).

Bone pain and radiographic features of osteosclerosis may present as an early prodromal phase (sometimes referred to as “stage 0”) of ONJ. In such individuals, it is essential to exclude other conditions that can cause odontalgia as listed in Table 1. Such individuals require close follow-up to ensure early detection of ONJ should it develop.

As approximately 50% of such lesions do not progress to clinically evident ONJ, the International Task Force on ONJ did not include preclinical ONJ as a defined stage of this condition.

Why Does ONJ Develop?

The pathophysiology of ONJ is still unclear. It is not known whether necrosis precedes or follows infection. Infection and inflammation clearly play a significant role in the development of ONJ (22–26). BPs may increase the risk of local infection and may possibly contribute to impaired healing of the oral mucosa (27–32). BPs may also activate gamma delta T cells with altered production of proinflammatory cytokines and impairment of the immune response to infection (33–35). Suppression of bone remodeling by BPs or denosumab may also contribute to the development of ONJ (36–41). Antiangiogenic properties of high doses of BPs have been reported as a possible mechanism for the development of ONJ (42–44). It is possible that BPs may affect monocyte and macrophage function and survival contributing to an increased risk of ONJ. There may be genetic susceptibility to the development of ONJ with polymorphisms in the cytochrome P450 gene, CYP2C8 gene, or farnesyl pyrophosphate synthase gene, which may increase the risk of developing ONJ (45–47).

Are Biomarkers Useful in Predicting the Risk of ONJ?

Investigators have suggested that serum C-terminal telopeptide (sCTX), a marker of bone resorption, would be useful in predicting the risk of ONJ (48). Based on data from only 17 patients who developed ONJ following therapy with alendronate or risedronate, it was proposed that a serum sCTX value of >0.15 ng/ml constituted a low risk of ONJ; sCTX values between 0.10 and 0.15 ng/ml indicated a moderate risk; and sCTX values <0.10 ng/ml implied a high risk of ONJ. It was further suggested that surgery should be avoided in high-risk individuals identified with bone turnover markers. Studies in individuals with ONJ,

Osteoporosis Medications, Dental Health, and Osteonecrosis of the Jaw (ONJ):**What You Need to Know**

Brought to you by the International Task Force on ONJ

Osteoporosis causes bones to become weak and break (fracture) easily. These fractures can happen from simple falls or even from usual day-to-day activities (eg lifting, bending). Any bone can fracture with osteoporosis; however, the most common fractures are of the spine, hip, and wrist. Osteoporosis can affect men and women of all ages but is most common amongst women after menopause.

Fractures from osteoporosis are preventable with appropriate medications. Bisphosphonates are a class of drugs which can safely and effectively decrease the risk of fracture in osteoporotic patients. They represent a major advance in the treatment of osteoporosis and other bone diseases. Some of the oral bisphosphonates which are commonly prescribed include alendronate (Fosamax, Binosto), ibandronate (Boniva) and risedronate (Actonel, Atelvia). Zoledronic acid (Aclasta, Reclast) given intravenously once yearly is also used for osteoporosis. Bisphosphonates remain in the skeleton for several years even after they are stopped. Bisphosphonates help reduce the risk of fracture and help maintain healthy bones. Denosumab (Prolia) is also an effective treatment for osteoporosis and can effectively lower the risk of fracture. Denosumab is given twice yearly by subcutaneous injection and does not remain in the skeleton for prolonged periods of time.

What is Osteonecrosis of the Jaw?

Osteonecrosis of the jaw (ONJ) is a rare oral condition in which the jaw *bone's* ability to heal is impaired and may cause a wound which does not heal. The bone is bare and is not covered by the oral tissues. This bare bone can become infected and lead to pain and swelling. The bone can then break and the infection may be difficult to heal. ONJ does not affect the jaw *joint* (*temporomandibular joint* or *TMJ*), and pain or discomfort in the jaw *joint* is not related to ONJ or to bisphosphonate or denosumab treatment. Though sometimes painful and progressive, ONJ can be present without symptoms; it usually heals with appropriate treatment.

How is ONJ Diagnosed?

Dentists or oral surgeons can diagnose ONJ by examining the soft tissue covering the jaw bones. If the jaw bone is not covered by a healthy soft tissue lining and remains uncovered or exposed for more than 8 weeks of appropriate treatment, this confirms the diagnosis of ONJ.

ONJ can occur in the general population in the absence of any bisphosphonate or denosumab therapy or other drugs, and usually heals within 12 weeks. ONJ can also develop in people who have risk factors for ONJ including poor blood supply to the bone cells in the jaw. It can also develop after major dental surgery which involves cutting the bone, chemotherapy, steroid therapy (such as prednisone) and from poor dental health and diabetes.

Is ONJ Caused by the Osteoporosis Therapy -- Bisphosphonates or Denosumab?

ONJ has been noted in patients with cancer receiving high doses of intravenous zoledronic acid or denosumab to reduce the complications associated with cancer that has spread to the bones. In these patients, the risk increases with higher doses and with longer duration of treatment. In patients with cancer, ONJ has been estimated to occur in 1 to 15% of individuals receiving high dose bisphosphonate or denosumab therapy.

In patients with osteoporosis, denosumab or bisphosphonate medications are used in lower doses (much lower than in patients with cancer) and the risk appears to be only minimally higher than seen in the general population not taking any bisphosphonate or denosumab therapy. The risk of ONJ with low dose bisphosphonate or denosumab treatment in osteoporosis patients is estimated to be between 1 in 10,000 and 1 in 100,000 per year of use and appears to be increased only slightly, if at all, compared with the risk for ONJ in the general population who have not taken any osteoporosis therapy.

Fig. 1. ONJ patient brochure. ONJ, osteonecrosis of the jaw.

How can ONJ be Prevented?

The International ONJ Task Force recommends that everyone should maintain good oral hygiene and see their dentist every 6 months (or as recommended based on oral disease risk). Routine dental work, such as dental cleaning, fillings or root canals should be performed as usual and do not require stopping your osteoporosis treatment.

It is important to stop smoking. If possible, before starting high dose intravenous bisphosphonate or denosumab therapy in patients with cancer, a detailed dental examination should be completed with X-rays of the jaw bones. Any necessary dental surgery should be completed before starting high dose intravenous bisphosphonate or denosumab therapy in patients with cancer.

The recommendations for patients with osteoporosis receiving low dose bisphosphonate or denosumab therapy are similar to those which apply to all individuals. They include maintenance of good oral hygiene and visiting your dentist regularly. If oral surgery is needed, it is ideal to have the surgery completed before starting low dose oral or intravenous yearly bisphosphonate therapy or denosumab therapy if possible. Individuals with risk factors for ONJ who are taking bisphosphonate or denosumab therapy may be advised to stop treatment after dental surgery and to restart therapy after the surgical site has completely healed. This usually takes place 1-2 months after the surgery. As bisphosphonates and denosumab are extremely important in preventing fractures, this should be discussed with the health care provider who prescribed the osteoporosis treatment.

How is ONJ Treated?

If ONJ does occur, treatment is usually managed by the dentist and/or oral surgeon and includes maintaining good oral hygiene, controlling pain and treating areas of infection with antibiotics and oral antibiotic mouth rinses. Making sure patients take lots of fluids and appropriate nutrition is also necessary. In certain circumstances, surgical treatment is required to remove dead bone tissue. This will be determined by the dentist and oral surgeon.

Summary:

The International Task Force on Osteonecrosis of the Jaw has been established to look at research priorities in order to help us understand the causes of ONJ as well as the most effective forms of treatment.

Osteoporosis is a serious disease. Treatment with bisphosphonates or denosumab is a safe and effective way to reduce your chances of breaking a bone. Talk to your doctor about your concerns and make sure your dentist is aware if you are taking a bisphosphonate or denosumab.

If you are experiencing any of the following symptoms please contact your dentist:

Infection of the gum, drainage of the gums, poor gum healing, numbness of the jaw, jaw pain or swelling or bare bone in the mouth.

A JOINT MESSAGE FROM

The International Task Force on ONJ : ASBMR, AAOMS, CAOMS, CAOMP, ECTS, IBMS, IOF, ISCD, IAOMS, JSBMR, NOF, Osteoporosis Canada, PAOS, TES

Fig. 1. (Continued)

however, have not shown a relationship between sCTX and the development of ONJ lesions (48–53). Multiple randomized, placebo-controlled trials have confirmed that BP therapy reduces sCTX and other markers of bone turnover often in excess of 50%. In a randomized trial comparing zoledronic acid annual infusion to placebo (HORIZON study) in 7756 postmenopausal women, the mean sCTX values at 6 mo were at the low end of the pre-

menopausal reference range (0.04–0.18 ng/ml) (54). If the criteria proposed by Marx et al (48) were justified, these patients would be moderate- or high-risk; there were just 2 cases of ONJ, one in the zoledronic acid group and the other in the placebo group. The individual with ONJ on zoledronic acid was not in the subset being evaluated with biomarkers and sCTX was not available. The individual with ONJ on placebo did not have a suppressed sCTX and would

Table 1
Causes of Odontalgia to Be Excluded Before
Considering the Presence of Early Prodromal Phase of
Osteonecrosis of the Jaw

Necrotic dental pulp with apical abscess
Periodontal abscess
Reversible or irreversible pulpitis (could be secondary to bruxism)
Maxillary sinus pain (acute or chronic sinusitis)
Myofascial pain
Dental caries
Neoplastic process in the jaw
Any soft tissue lesion of the alveolar mucosa such as an ulceration causing regional pain

have been considered at low risk of ONJ based on the criteria proposed.

BP therapy commonly lowers sCTX to <0.15 ng/ml; however, ONJ is rare. Low sCTX is simply a reflection of the pharmacological effects of antiresorptive therapy and is not useful in identifying individuals at risk for ONJ.

How Common Is ONJ?

The incidence of ONJ in the osteoporosis patient population has been estimated from controlled clinical trials, case series, retrospective observational studies, or retrospective cohort studies. Currently, prospective data evaluating the frequency of ONJ in the osteoporosis patients are limited. The incidence of ONJ from retrospective administrative database data, especially pooled data from insurance or healthcare databases, is difficult to accurately evaluate. The search terms used may not be reflective of the underlying condition. In osteoporosis patients, the prevalence of ONJ has been estimated to be very low in the magnitude of 0.001%–0.01% as estimated from national surveys completed in Australia, Canada, Germany, United States, and Sweden (39,55–57).

In the US Kaiser Permanente database, the prevalence of ONJ with BP use ranged from 0.05% to 0.21% and appeared to be related to duration of exposure (58). In the HORIZON study, 2 cases of ONJ were observed, one in the placebo group and one in the active therapy group. Four additional randomized controlled trials evaluating 5 mg zoledronic acid in comparison to placebo were reviewed. The adverse event database for 60 MedDRA search terms revealed no additional cases of ONJ. The incidence of adjudicated ONJ in 5903 individuals treated with zoledronic acid in 5 clinical trials was less than 1 in 14,200 patient-treatment years (54). The incidence of ONJ in the osteoporosis patient population is very low and may be only slightly higher than the frequency seen in the general population. Regardless of the very low risk, it is necessary to

identify those individuals at higher risk and to take steps to minimize the occurrence of ONJ and its progression.

In the FREEDOM clinical trial of denosumab vs placebo involving almost 8000 postmenopausal osteoporotic women over 3 yr, there were no cases of ONJ. This clinical trial was extended with all patients on open label denosumab, and by the end of 7–10 yr of exposure, 13 cases of ONJ were identified (38,59).

In all cases where the outcome of ONJ was known, healing occurred with conservative therapy and frequent medication was continued without interruption. Estimated total postmarketing exposure to denosumab is 1,960,405 patient-years in 2,427,475 patients as of May 2014 (60). In this large patient exposure, 47 adjudicated cases of ONJ based on the AAOMS criteria have been confirmed. All of these individuals had at least one other risk factor for ONJ including concurrent glucocorticoid use, concurrent chemotherapy, prior BP use, or invasive dental procedures. The ONJ lesions resolved in a third of the cases and are ongoing in another third. The status of the remaining one third is not known (61).

The postmarketing data suggest that the risk of ONJ in the osteoporosis patient population with either BPs or denosumab appears to be only slightly higher than the risk seen in the general population.

OUBS unrelated to antiresorptive therapy may confound these postmarketing data because clinical features may be similar to early-stage ONJ. OUBS lesions can persist for variable time periods ranging from a few days to several months and usually heal with conservative therapy (62,63).

The incidence of ONJ in oncology patient populations is much higher than that seen in osteoporosis patient populations (64–76). There are reasonable data evaluating this finding, including limited prospective studies, retrospective studies, and case series. A recent meta-analysis of 7 randomized controlled trials concluded that the incidence of ONJ in cancer patients receiving denosumab was 1.7% (95% confidence interval: 0.9%–3.1%) (77). In individuals receiving high-dose BP therapy, the incidence of ONJ is between 1% and 15% and appears to be related to dose and duration of exposure (64–76). There is considerable variability in the reported incidence and prevalence of ONJ in association with monthly administration of intravenous (IV) zoledronic acid or pamidronate in oncology patients. There may be confounding variables in this oncology population, including the use of other drugs that impact bone health (glucocorticoid and antiangiogenic drugs including thalidomide, bevacizumab, or sunitinib). There may also be other risk factors for ONJ such as chemotherapy, poor dental hygiene, neutropenia, and pre-existing local infection. The rate of resolution of ONJ may be more rapid in those treated with denosumab in comparison to BPs; however, this finding also requires further prospective data.

The use of IV BP and denosumab in oncology patients involves doses 12–15 times higher than what is used for postmenopausal osteoporosis. As an example, osteoporosis doses of denosumab are 60 mg biannually, and oncology doses to prevent progression of metastatic bone disease is 120 mg

monthly. Therefore, it is not surprising that ONJ is documented more frequently in the oncology population than in the osteoporosis population. The incidence of ONJ was obtained prospectively in 5723 patients with metastatic bone disease enrolled in 3 identical registration trials allowing pooling of data in the comparison of denosumab 120 mg monthly with zoledronic acid 4 mg monthly, where oral exams were completed every 6 mo. There were 89 adjudicated cases of ONJ: 37 (1.3%) were in the zoledronic acid group and 52 (1.8%) were in the denosumab group ($p = 0.13$) (78). The median exposure to the agent was 14 mo in both groups (69,79,80).

Both denosumab and BP therapies in oncology patients result in a clinically significant reduction in the risk of skeletal-related events (which occurred in 35.2% of the studied population) in comparison to the relatively low risk of ONJ of 1.6% (69). Thus, the benefit of high-dose antiresorptive therapy outweighed the risk of ONJ by a factor of 17.

What Is the Role of Imaging in the Diagnosis and Management of ONJ?

Plain radiographs are useful in evaluating the presence of early changes seen with ONJ such as thickening of the lamina dura, increased trabecular density of the alveolar bone, or widening of the periodontal ligament space (81,82). The presence of sequestrum may also be identified on plain films. Limitations of intraoral X-rays include assessment of only a small portion of the mandible and maxilla as well as distortion of the anatomy. Imaging techniques, however, are useful screening tools for the presence of dental disease and the assessment of the severity and extent of ONJ. Imaging is also helpful in the follow-up of patients with ONJ.

Computed tomography (CT) has many advantages over plain films and allows assessment of cortical and trabecular architectures of the maxilla and the mandible. Cortical integrity, periosteal bone reaction, and sequestrum formation can be clearly identified. In ONJ patients, diffuse osteosclerosis is seen (83,84). Thickening of the cortical outline and periosteal bone formation are often present. Sequestration and early fistula track formation as well as incomplete extraction socket healing may be noted (83,85–88). Increased trabecular bone density, which may not be seen on plain films, may be identified on CT images (89). Cone-beam CT provides the same advantages as CT while incurring a significantly lower radiation exposure.

Magnetic resonance imaging (MRI) is useful in identifying the early features of ONJ before the development of exposed bone. A decrease in bone marrow signal intensity on T1-weighted images may be present before the development of the clinical features of ONJ (84,85,90,91). T2-weighted and short T1 inversion-recovery may show increased signal intensity due to bone edema (85,92). With advanced disease, the exposed bone shows decreased signal

intensity and the unexposed diseased bone shows increased signal intensity. Sequestra as well as the presence of soft tissue thickening, edema, and lymphadenopathy can also be identified on MRI (90,93). Therefore, MRI does have advantages over CT in evaluating the presence of ONJ, especially in the early stages of the disease.

Isotope bone scanning and positron emission tomography (PET) are sensitive techniques for the detection of early disease. Isotope bone scans have high sensitivity in assessing early disease. PET alone or in combination with CT is also of value in assessing the severity of ONJ. Individuals on antiresorptive therapy experiencing symptoms of bone pain without evidence of exposed bone on oral examination may benefit from radiographic assessment. If the initial panoramic radiographs are unremarkable, they should be repeated at intervals.

In those individuals receiving high-dose IV BPs or denosumab therapy in whom the risk of developing ONJ is significant, early and accurate detection of dental disease is necessary. In such individuals, cone-beam CT imaging should be performed as it is superior to conventional radiographs in diagnosing periapical and periodontal diseases. For those individuals with stage 1 and stage 2 ONJ who are being managed conservatively, cone-beam CT is also helpful in identifying the extent of osteonecrotic change. Additional imaging with MRI, isotope bone scanning, or PET may be of value in patients in whom there might be consideration of surgical intervention.

What Are the Risk Factors for the Development of ONJ?

In the oncology patient population, there are a number of risk factors associated with increased risk of ONJ. In a prospective analysis of ONJ in oncology patients, the majority of patients with ONJ had a precipitating oral event. This included a tooth extraction in approximately two thirds of the patients, coincident oral infection in approximately half of the patients, or other risk factors (69). Corticosteroid use was more common in patients who developed ONJ (73% with ONJ vs 62.3% without ONJ). Also, the use of antiangiogenic agents was associated with an increased risk of ONJ (15.7% with ONJ vs 8% without ONJ). Anemia and diabetes were associated with only a slight increase in the risk of ONJ. Forty-five percent of those with anemia (defined as hemoglobin <10 g/dL) developed ONJ in comparison to 40.9% without anemia. Approximately 22.5% of those with diabetes developed ONJ in comparison to 15.5% without diabetes.

In the oncology population, the risk of ONJ appears to increase in the presence of the following risk factors: IV BP (dose and duration dependent), denosumab, dental extraction, chemotherapy, periodontal disease, oral BP, glucocorticoid, diabetes mellitus, denture use, smoking, hyperthyroidism, dialysis, antiangiogenics, and older age (Table 2).

Table 2
Significant Risk Factors for the Development of Osteonecrosis of the Jaw

Risk factor	Population	Univariate estimates ^a	Multivariate estimates ^a
Age (per decade)	Oncology		OR = 1.09 (94)
Age (per year)	Oncology	OR = 1.1 (65)	
Anemia	Osteoporosis		OR = 5.2 (95)
Bisphosphonate use	Osteoporosis	OR = 14.9 (96)	HR = 2.23–3.15 (97) OR = 2.8 (98)
Bisphosphonate use	Oncology	OR = 14.9 (96)	OR = 1.06–299.5 (71,76,95,99–101) RR = 9.5 (99) HR = 2.23–3.15 (97) OR = 1.78–2.02 (76)
Bisphosphonate use—per dose	Oncology		
Chemotherapy	Oncology	OR = 3.4 (65)	
Chemotherapy and concomitant BP	Oncology	OR = 29.11 (102)	
Denosumab	Osteoporosis or oncology		Increased risk inferred from incidence and prevalence data
Dental extraction	Osteoporosis		OR = 6.6 (95)
Dental extraction	Oncology	OR = 5.3 (65)	OR = 9.09–53.2 (76,94,95,100,103)
Denture use	Oncology		OR = 1.43–4.9 (76,103,104)
Diabetes	Oncology		HR = 3.40 (105)
Erythropoietin therapy	Oncology	OR = 3.9 (65)	
Glucocorticoid therapy	Oncology	OR = 6.5 (65)	
Glucocorticoid therapy	Oncology or osteoporosis	OR = 2.8 (96)	
Hyperthyroidism	Oncology		HR = 3.59 (105)
Hemoglobin low	Oncology	OR = 6.8 (65)	
Male gender (vs female)	Oncology		HR = 1.68 (63)
Osteoporosis	Oncology		OR = 6.11 (100)
Osteoporosis	Oncology or osteoporosis	OR = 10.3 (96)	
Periodontitis	Oncology		OR = 2.95–13.0 (104)
Radiation therapy	Oncology		OR = 24.1 (95)
Renal dialysis	Oncology	OR = 3.2 (65)	
Smoking tobacco	Oncology	OR = 6.0 (106)	HR = 3.44 (105)
Suppuration	Osteoporosis		OR = 11.9 (95)
Suppuration	Oncology		OR = 7.8 (95)

Note: Comparators of disease states are with the population group without disease state.

Abbr: BP, bisphosphonate; HR, hazard ratio; ON, oncology; OR, odds ratio; RR, relative risk.

^aOnly statistically significant ($p < 0.05$) associations are reported on this table.

In osteoporosis patients, the following are important risk factors for ONJ: suppuration, dental extraction, oral BP, and denosumab (Table 2).

Our patient has a number of risk factors including long-term use of BP, diabetes, prednisone, smoking, and poor dental hygiene.

Can ONJ Be Prevented and Should Her BP Be Stopped?

To minimize the development of ONJ in patients at risk, regular dental examinations are encouraged. Oral hygiene should be improved and local infection managed as early as possible (107–110). The use of antibiotics before and after

oral surgical procedures has been demonstrated to lower the risk of ONJ (107,108,111–113).

Antimicrobial mouth rinses may also be of value in lowering the risk of ONJ (108,111).

All necessary oral surgeries in oncology patients should ideally be completed before the initiation of high-dose antiresorptive therapy (112,114–116). For oncology patients requiring high-dose IV BPs or high-dose denosumab, dental radiographs should be completed before the initiation of therapy to identify the disease before medication begins. Any invasive dental procedure including dental extractions or implants should ideally be completed before the initiation of antiresorptive therapy. Nonurgent procedures should be delayed if necessary. If ONJ develops,

it is recommended that the antiresorptive drug therapy be withheld until soft tissue closure with a well-epithelialized mucosa is achieved.

There is currently no evidence that interruption of drug therapy in patients requiring dental procedures reduces the risk of ONJ or the progression of the disease. There are a number of factors that need to be considered when evaluating the suitability of the interruption of antiresorptive therapy. BPs that have long-term skeletal retention and cessation for weeks or months may not impact remodeling significantly. However, BPs do have increased skeletal uptake at the sites of local bone injury (isotope bone scan uses labeled BP), and withholding BP therapy following oral surgery may be of value in reducing the local deposition in the mandible and maxilla after oral surgery. In individuals with significant risk factors for ONJ, including oncology patients on high-dose antiresorptive therapy as well as those individuals with multiple risk factors for ONJ, it may be of benefit to withhold BP or denosumab therapy following oral surgery until soft tissue healing occurs.

In determining the suitability of drug interruption, it is necessary to weigh the risks of ONJ with the risk of skeletal-related events in oncology patients and the risk of fracture in those with osteoporosis. The decision to hold therapy should be jointly made between the oral surgeon and the physician treating the underlying osteoporosis. The treatment plan must be individualized for each patient based on comorbidity, risks for ONJ, extent of the planned surgery, as well as the risks for fracture and skeletal-related events.

Patients with osteoporosis receiving BP or denosumab may continue with therapy if a dental procedure (including extractions and implant surgery) is required (117). The decision to continue or hold antiresorptive therapy should be made by the dental health provider in consultation with the patient's physician. This approach is the collective opinion of our task force based on our current understanding of this disease. There are a few published case reports suggesting improved healing of ONJ with the use of teriparatide (118,119).

Our patient has a high 10-yr fracture risk based on FRAX. FRAX recognizes risk factors of prevalent fragility fracture (vertebral fracture in our patient), family history of hip fracture, current cigarette smoking, high alcohol intake, rheumatoid arthritis, prednisone therapy, and other secondary causes of bone loss. Type 2 diabetes (our patient has a 15-yr history of type 2 diabetes mellitus) is a risk factor elevating patients' fracture risk but is not recognized as a FRAX risk factor, and may be a risk not be captured by BMD (120). Our patient also has been on prednisone therapy 5 mg daily for more than 3 mo and is a current smoker. Based on the patient's femoral neck BMD of 0.562 gm/cm² (*T*-score of -2.6), her fracture risk would be calculated by FRAX over the next 10 yr to be 34% for major osteoporotic fracture (clinical vertebral, wrist, hip, and humerus fractures). The patient's risk of hip fracture would be 14% over the next 10 yr, and she is at high risk of fracture.

The patient's risk of ONJ with long-term BP is low; however, she also has other important risk factors for the development of ONJ, including history of diabetes, glucocorticoid use, and poor dental hygiene. The patient's BP may be stopped until her dental procedure is complete and the wound healed. Should the patient develop ONJ, teriparatide would be an effective treatment for osteoporosis and may also be of value in healing ONJ.

How Should ONJ Be Managed?

Management is based on the stage of ONJ, the size of the lesions, the presence of the contributing drug therapy, and medical and pharmacological comorbidities. Figures 1 and 2 provide ONJ management guides for the patient and physician, respectively, and Table 3 summarizes the treatment options for ONJ.

Conservative therapy of ONJ focuses on improving oral hygiene, treating active dental and periodontal diseases, topical antibiotic mouth rinses, and systemic antibiotic therapy (21,67,117,170). There are several case reports of the successful treatment of ONJ with teriparatide, which are encouraging; these reports may be considered to facilitate wound healing (119,171). Teriparatide is contraindicated in individuals who have had skeletal radiation and may not be a useful intervention approach for those with malignancy and a prior history of skeletal irradiation.

Experimental treatment approaches require further validation. These treatment approaches include topical ozone (164), bone marrow stem cell intralésional transplantation (172), and addition of pentoxifylline and tocopherol to standard antibiotic regimens (147). Laser therapy has also been proposed to be of benefit (151,173). Localized surgical debridement may be indicated; some authors have reported success with larger resections compared to limited debridement or conservative therapy (121,174). Enhanced healing has been observed in a retrospective survey of patients undergoing antibiotic therapy in addition to surgery followed by low-level laser therapy (157). Surgery, together with platelet-derived growth factor applied to the local site, has achieved good results in stage 2 ONJ cases (175). Hyperbaric oxygen in combination with surgery has been investigated with encouraging results (122,161). Further research is required with these new strategies.

In the absence of debilitating ONJ lesions, it is recommended that conservative therapy consisting of optimal oral hygiene, topical antibiotic rinses, and systemic antibiotics be initiated (112). Nonresponsive cases should be considered for surgery including osteotomy of the affected area with resection margins extending into adjacent normal appearing bone. Soft tissue closure should be completely tension free with no underlying sharp edges of bone that could lead to mucosal breakdown. Microvascular composite tissue grafting at the time of surgical resection may be considered in the presence of a pathological fracture or ONJ if the extension is to the sinus or the inferior border of the mandible. It may also be of value if the osteotomy to healthy

ONJ Key Recommendations for Clinicians**PREVENTION OF ONJ IN PRESENCE OF BISPHOSPHONATE OR DENOSUMAB THERAPY****A. Evaluate Key Risk Factors for ONJ:**

- Invasive dental procedure
- Diabetes
- Glucocorticoid therapy
- Periodontal disease
- Denture use
- Smoking
- Anti-angiogenic agents

B. Evaluate Fracture risk:**1. If risk of ONJ is increased and**

a. risk of fracture is low (< 10% over next 10 years) or moderate (10%-20% over the next 10 years) then stop antiresorptive therapy

b. risk of fracture is high ($\geq 20\%$ over next 10 years) and major invasive oral surgery is planned, consider stopping antiresorptive therapy. Consider the use of teriparatide during the time off antiresorptive therapy if no contraindications. If contraindication to teriparatide (hypercalcemia, high PTH levels, prior skeletal radiation, malignancy, elevated alkaline phosphatase) are present stop antiresorptive therapy after dental procedure until surgical site heals

c. In all patients with increased risk of ONJ consider antimicrobial mouth rinses, antibiotics and always emphasize good oral hygiene

2. If risk of ONJ is low and

a. risk of fracture is moderate or high, then continue antiresorptive therapy

C. Staging:

- **Stage 1:** Exposed bone, asymptomatic
- **Stage 2:** Exposed bone with associated pain, adjacent or regional soft tissue inflammatory swelling or secondary infection
- **Stage 3:** As above + one or more of the following: pathological fracture, extra-oral fistula, oral antral fistula, or radiographic evidence of osteolysis extending to the inferior border of the mandible or the floor of the maxillary sinus

D. Treatment:

Management is determined by stage, severity of symptoms, functional impairment and overall prognosis

- **Stage 1:** conservative therapy – improve oral hygiene. Treat active dental and periodontal disease, topical antibiotic mouth rinses
- **Stage 2:** as in stage 1 also Rx symptoms, systemic antibiotics if infection is suspected, consider surgical debridement
- **Stage 3:** as in stage 1 also surgical debridement, resection including jaw reconstruction if necessary

Guidelines developed by: ASBMR, AAOMS, CAOMS, CAOMP, ECTS, IBMS, IOF, ISCD, IAOMS, JSBMR, NOF, OSTEOPOROSIS CANADA, PAOS, TES.

Fig. 2. Physicians' quick reference card for ONJ diagnosis and treatment. ONJ, osteonecrosis of the jaw.

Table 3
Summary of ONJ Treatments

Treatment type and supportive trial or study (≥ 5 patients)	Notes
Bone resection (121–130)	Many supporting trials used concomitant antibiotics and demonstrated excellent efficacy in healing ONJ; not all trials demonstrated high cure rates following surgery (69,131–133).
Surgical debridement (130,134–136)	Often with antimicrobial rinsing, very successful technique with minority requiring subsequent sequestrectomy
Sequestrectomy (126,128,137–140)	Often successful with antibiotics
Prophylactic antibiotics before or immediately after surgery (111,125,136,137,141,142)	Antibiotics substantially decrease the rate of recurrence.
Nonsurgical long-term antibiotics (143,144)	Some trials showed success with antiseptic rinse, smoothing, and removal of necrotic bone with tweezers; no difference between it and surgical care with respect to remission; some trials with antibiotic-only approach without surgery had limited success (126,145,146).
Nonsurgical antiseptic rinse (144)	Some trials demonstrated success with long-term antibiotics, smoothing, and removal of necrotic bone with tweezers.
Antimicrobial rinse (intravenous) (121,130,139,140,147,148)	Usually successful in combination with surgery; longer-term antimicrobial therapy before surgery more effective; in some trials, not as effective as primary treatment (145,149,150) or with surgery (133)
Er:YAG laser therapy (151–153)	Er:YAG laser therapy found to be effective in most trials, but not all (154)
Nd:YAG laser (155,156)	Majority have complete healing; others have shown significant improvement in symptoms.
Low-level laser therapy (157–160)	Often in combination with medical or surgical therapy; used primarily for reduction in pain, but also improvements in defect size, edema, and presence of pus and fistulas
Hyperbaric oxygen therapy (161–163)	As an adjunct to other therapies such as antibiotics, antiseptics, and surgery; often for symptomatic relief (142); not always found to have clinical impact (133,149)
Ozone therapy (164–167)	Some supporting trials used concomitant antibiotics; germicidal and analgesic effects
Plasma rich in growth factor therapy (109)	Shown to be very successful in combination with surgery
Autologous platelet-rich plasma (157,168)	During partial bone resection of patients that failed conservative therapy—80% success in 1 trial; used with laser therapy as well
Platelet-derived growth factor (123)	With bone resection
Recombinant human bone morphogenetic protein type 2 therapy (169)	All patients healed after 1 yr
Pentoxifylline and alpha-tocopherol therapy (147)	With adjunct antimicrobial therapy

Abbr: ONJ, osteonecrosis of the jaw.

tissue leads to a discontinuity defect. This is a rapidly evolving area of investigation and further recommendations will be forthcoming.

In conclusion, the pathophysiology of ONJ is still poorly understood and appears to be multifactorial, with infection playing a key role in the development of ONJ. Drugs have

also been associated with ONJ and include antiresorptive agents, amino-BPs, and denosumab, particularly when administered in high doses in the oncology patient population. The benefits of antiresorptive therapy far outweigh the potential risks with major reductions in skeletal-related events in the oncology patient and fracture risk

reduction in the osteoporosis patient. Risk stratification with implementation of ONJ preventive strategies is helpful in reducing the risk of ONJ. Emphasizing good oral hygiene as well as the use of antimicrobial mouth rinses and effective treatment of oral infection is of benefit in improving clinical outcomes. Lower doses of antiresorptive therapy coupled with appropriate use of anabolic therapy may also be of value and require further study. The diagnostic and prognostic factors for ONJ need to be further refined to more effectively identify patients at high risk. Current ongoing prospective studies of patients at risk are expected to provide future insights into clinically useful predictors of ONJ and more effective intervention options for both the osteoporosis patient and the oncology patient populations.

References

1. Khan AA, Morrison A, Hanley DA, et al. 2015 Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 30:3–23.
2. Marx RE. 2003 Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 61:1115–1117.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg* 62:527–534.
4. Khosla S, Burr D, Cauley J, et al. 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 22:1479–1491.
5. Schwartz HC. 2015 American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update and CTX. *J Oral Maxillofac Surg* 73:377.
6. Peters E, Lovas GL, Wysocki GP. 1993 Lingual mandibular sequestration and ulceration. *Oral Surg Oral Med Oral Pathol* 75:739–743.
7. Sonnier KE, Horning GM. 1997 Spontaneous bony exposure: a report of 4 cases of idiopathic exposure and sequestration of alveolar bone. *J Periodontol* 68:758–762.
8. Scully C. 2002 Oral ulceration: a new and unusual complication. *Br Dent J* 192:139–140.
9. Flaitz CM. 2000 Oral and maxillofacial pathology case of the month. Lingual mandibular sequestration and ulceration. *Tex Dent J* 117:34, 40–41.
10. Farah CS, Savage NW. 2003 Oral ulceration with bone sequestration. *Aust Dent J* 48:61–64.
11. Kessler HP. 2005 Oral and maxillofacial pathology case of the month. Lingual mandibular sequestration with ulceration. *Tex Dent J* 122:198–199.
12. Jackson I, Malden N. 2007 Lingual mucosal ulceration with mandibular sequestration. *Dent Update* 34:573–577.
13. Danesh-Meyer MJ. 1999 Spontaneous alveolar bone sequestration. Case reports. *J N Z Soc Periodontol* 84:18–20.
14. Peters E, Daley T. 2003 Persistent painful ulcer of the posterior lingual mandibular mucosa. *J Contemp Dent Pract* 4:71–75.
15. Almazrooa SA, Chen K, Nascimben L, et al. 2010 Case report: osteonecrosis of the mandible after laryngoscopy and endotracheal tube placement. *Anesth Analg* 111:437–441.
16. de Visscher JG, Dietvorst DP, van der Meij EH. 2013 [Lingual mandibular osteonecrosis]. *Ned Tijdschr Tandheelkd* 120:189–193.
17. Walter C, Grotz KA, Kunkel M, Al-Nawas B. 2007 Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. *Support Care Cancer* 15:197–202.
18. Walter C, Al-Nawas B, Grotz KA, et al. 2008 Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. *Eur Urol* 54:1066–1072.
19. Ruggiero SL, Fantasia J, Carlson E. 2006 Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 102:433–441.
20. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. 2007 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. *J Oral Maxillofac Surg* 65:369–376.
21. Ruggiero SL, Dodson TB, Assael LA, et al. 2009 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update. *Aust Endod J* 35:119–130.
22. Marx RE, Sawatari Y, Fortin M, Broumand V. 2005 Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofac Surg* 63:1567–1575.
23. Lesclous P, Abi NS, Carrel JP, et al. 2009 Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? *Bone* 45:843–852.
24. Sedghizadeh PP, Kumar SK, Gorur A, et al. 2009 Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. *J Am Dent Assoc* 140:1259–1265.
25. Nair SP, Meghji S, Wilson M, et al. 1996 Bacterially induced bone destruction: mechanisms and misconceptions. *Infect Immun* 64:2371–2380.
26. Meghji S, Crean SJ, Hill PA, et al. 1998 Surface-associated protein from *Staphylococcus aureus* stimulates osteoclastogenesis: possible role in *S. aureus*-induced bone pathology. *Br J Rheumatol* 37:1095–1101.
27. Hikita H, Miyazawa K, Tabuchi M, et al. 2009 Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. *J Bone Miner Metab* 27:663–672.
28. Landesberg R, Woo V, Cremers S, et al. 2011 Potential pathophysiological mechanisms in osteonecrosis of the jaw. *Ann N Y Acad Sci* 1218:62–79. doi:10.1111/j.1749-6632.2010.05835.x.
29. Ravosa MJ, Ning J, Liu Y, Stack MS. 2011 Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. *Arch Oral Biol* 56:491–498.
30. Pabst AM, Ziebart T, Koch FP, et al. 2012 The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study. *Clin Oral Investig* 16:87–93.
31. Yamashita J, Koi K, Yang DY, McCauley LK. 2011 Effect of zoledronate on oral wound healing in rats. *Clin Cancer Res* 17:1405–1414.
32. Allam E, Allen M, Chu TM, et al. 2011 In vivo effects of zoledronic acid on oral mucosal epithelial cells. *Oral Dis* 17:291–297.

33. Kunzmann V, Bauer E, Wilhelm M. 1999 Gamma/delta T-cell stimulation by pamidronate. *N Engl J Med* 340:737–738.
34. Kunzmann V, Bauer E, Feurle J, et al. 2000 Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. *Blood* 96:384–392.
35. Das H, Wang L, Kamath A, Bukowski JF. 2001 Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. *Blood* 98:1616–1618.
36. Allen MR. 2007 Animal models of osteonecrosis of the jaw. *J Musculoskelet Neuronal Interact* 7:358–360.
37. Allen MR. 2009 Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. *Cells Tissues Organs* 189:289–294.
38. Papapoulos S, Chapurlat R, Libanati C, et al. 2012 Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. *J Bone Miner Res* 27:694–701.
39. Khan AA, Rios LP, Sandor GK, et al. 2011 Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. *J Rheumatol* 38:1396–1402.
40. Stopeck AT, Lipton A, Body JJ, et al. 2010 Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 28:5132–5139.
41. Fizazi K, Carducci M, Smith M, et al. 2011 Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 377:813–822.
42. Fournier P, Boissier S, Filleul S, et al. 2002 Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. *Cancer Res* 62:6538–6544.
43. Santini D, Vincenzi B, Dicuonzo G, et al. 2003 Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. *Clin Cancer Res* 9:2893–2897.
44. Vincenzi B, Santini D, Dicuonzo G, et al. 2005 Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. *J Interferon Cytokine Res* 25:144–151.
45. Marini F, Tonelli P, Cavalli L, et al. 2011 Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. *Front Biosci (Elite Ed)* 3:364–370.
46. English BC, Baum CE, Adelberg DE, et al. 2010 A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. *Ther Clin Risk Manag* 6:579–583. doi:10.2147/TCRM.S14303.
47. Sarasquete ME, Garcia-Sanz R, Marin L, et al. 2008 Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. *Blood* 112:2709–2712.
48. Marx RE, Cillo JE Jr, Ulloa JJ. 2007 Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. *J Oral Maxillofac Surg* 65:2397–2410.
49. Bagan JV, Jimenez Y, Gomez D, et al. 2008 Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. *Oral Oncol* 44:1088–1089.
50. Kwon YD, Ohe JY, Kim DY, et al. 2011 Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? *Clin Oral Implants Res* 22:100–105.
51. Kunchur R, Need A, Hughes T, Goss A. 2009 Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. *J Oral Maxillofac Surg* 67:1167–1173.
52. Lee CY, Suzuki JB. 2010 CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. *Implant Dent* 19:29–38.
53. O'Connell JE, Ikeagwani O, Kearns GJ. 2012 A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery? *Ir J Med Sci* 181:237–242.
54. Grbic JT, Black DM, Lyles KW, et al. 2010 The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. *J Am Dent Assoc* 141:1365–1370.
55. Felsenberg D. 2006 Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment. *Nat Clin Pract Endocrinol Metab* 2:662–663.
56. Mavrokokki T, Cheng A, Stein B, Goss A. 2007 Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. *J Oral Maxillofac Surg* 65:415–423.
57. Ulmner M, Jarnbring F, Topping O. 2014 Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. *J Oral Maxillofac Surg* 72:76–82.
58. Lo JC, O'Ryan FS, Gordon NP, et al. 2010 Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. *J Oral Maxillofac Surg* 68:243–253.
59. Watts NB, Grbic JT, McClung MR, et al. 2014 Evaluation of invasive oral procedures and events in women with postmenopausal osteoporosis treated with denosumab: results from the pivotal phase 3 fracture study extension. *J Bone Miner Res* 29.
60. Wagman RB. 2014. Estimated total post-marketing exposure to denosumab: personal communication.
61. Geller ML, Wagman RB, Ho P-R, et al. 2014 Findings from denosumab (Prolia®) post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. *J Bone Miner Res* 29.
62. Akinmoladun VI, Akadiri OA, Adeleye JO, Lasisi OA. 2008 An unusual case of total maxillary sequestration in a diabetic patient. *Afr J Med Med Sci* 37:395–398.
63. Fleisher KE, Jolly A, Venkata UD, et al. 2013 Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. *J Oral Maxillofac Surg* 71:513–519.
64. Durie BG, Katz M, Crowley J. 2005 Osteonecrosis of the jaw and bisphosphonates. *N Engl J Med* 353:99–102.
65. Jadu F, Lee L, Pharoah M, et al. 2007 A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. *Ann Oncol* 18:2015–2019.
66. Carstos VM, Zhu S, Zavras AI. 2008 Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. *J Am Dent Assoc* 139:23–30.

67. Khan AA, Sandor GK, Dore E, et al. 2009 Bisphosphonate associated osteonecrosis of the jaw. *J Rheumatol* 36:478–490.
68. Christodoulou C, Pervena A, Klouvas G, et al. 2009 Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. *Oncology* 76:209–211.
69. Saad F, Brown JE, Van PC, et al. 2012 Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Ann Oncol* 23:1341–1347.
70. Tosi P, Zamagni E, Cangini D, et al. 2006 Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. *Blood* 108:3951–3952.
71. Cafro AM, Barbarano L, Nosari AM, et al. 2008 Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. *Clin Lymphoma Myeloma* 8:111–116.
72. Pozzi S, Marcheselli R, Sacchi S, et al. 2007 Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. *Leuk Lymphoma* 48:56–64.
73. Abu-Id MH, Warnke PH, Gottschalk J, et al. 2008 “Bisphosy jaws”—high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. *J Craniomaxillofac Surg* 36:95–103.
74. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. 2007 Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. *J Natl Cancer Inst* 99:1016–1024.
75. Badros A, Terpos E, Katodritou E, et al. 2008 Natural history of osteonecrosis of the jaw in patients with multiple myeloma. *J Clin Oncol* 26:5904–5909.
76. Vahntsevanos K, Kyrgidis A, Verrou E, et al. 2009 Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. *J Clin Oncol* 27:5356–5362.
77. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. 2013 Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. *Cancer Treat Rev* 39:97–104.
78. Lipton A, Fizazi K, Stopeck AT, et al. 2012 Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. *Eur J Cancer* 48:3082–3092.
79. Smith MR, Saad F, Coleman R, et al. 2012 Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. *Lancet* 379:39–46.
80. Van den Wyngaert T, Wouters K, Huizing MT, Vermorcken JB. 2011 RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? *Support Care Cancer* 19:2035–2040.
81. Swei Y. 2013 Radiographic findings of bisphosphonate-related osteomyelitis of the jaw: investigation of the diagnostic points by comparison with radiation osteomyelitis, suppurative osteomyelitis, and diffuse sclerosing osteomyelitis. *Oral Radiol* 29:121–134.
82. White S, Pharoah M. 2008 *Oral radiology*. 6th ed. Maryland Heights, MO: Mosby.
83. Bianchi SD, Scoletta M, Cassione FB, et al. 2007 Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 104:249–258.
84. Stockmann P, Hinkmann FM, Lell MM, et al. 2010 Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. *Clin Oral Investig* 14:311–317.
85. Bedogni A, Blandamura S, Lokmic Z, et al. 2008 Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 105:358–364.
86. Elad S, Gomori MJ, Ben-Ami N, et al. 2010 Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation. *Clin Oral Investig* 14:43–50.
87. Fatterpekar GM, Emmrich JV, Eloy JA, Aggarwal A. 2011 Bone-within-bone appearance: a red flag for bisphosphonate-associated osteonecrosis of the jaw. *J Comput Assist Tomogr* 35:553–556.
88. Phal PM, Myall RW, Assael LA, Weissman JL. 2007 Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. *AJNR Am J Neuroradiol* 28:1139–1145.
89. Taguchi A, Akiyama H, Koseki T, Shimizutani K. 2013 Recognition of bisphosphonate-related osteonecrosis of the jaw among oral and maxillofacial radiologists: results from a questionnaire-based survey in Japan. *Oral Radiol* 29:98–104.
90. Krishnan A, Arslanoglu A, Yildirm N, et al. 2009 Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. *J Comput Assist Tomogr* 33:298–304.
91. Chiandussi S, Biasotto M, Dore F, et al. 2006 Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. *Dentomaxillofac Radiol* 35:236–243.
92. Arijji Y, Arijji E. 2013 Role of magnetic resonance imaging in diagnosis of bisphosphonate-related osteonecrosis of the jaw. *Oral Radiol* 29:111–120.
93. Popovic KS, Kocar M. 2010 Imaging findings in bisphosphonate-induced osteonecrosis of the jaws. *Radiol Oncol* 44:215–219.
94. Badros A, Weikel D, Salama A, et al. 2006 Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. *J Clin Oncol* 24:945–952.
95. Barasch A, Cunha-Cruz J, Curro FA, et al. 2011 Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. *J Dent Res* 90:439–444.
96. Fellows JL, Rindal DB, Barasch A, et al. 2011 ONJ in two dental practice-based research network regions. *J Dent Res* 90:433–438.
97. Vescovi P, Campisi G, Fusco V, et al. 2011 Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. *Oral Oncol* 47:191–194.
98. Lapi F, Cipriani F, Caputi AP, et al. 2013 Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. *Osteoporos Int* 24:697–705.
99. Zervas K, Verrou E, Teleioudis Z, et al. 2006 Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. *Br J Haematol* 134:620–623.
100. Hoff AO, Toth BB, Altundag K, et al. 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer

- patients treated with intravenous bisphosphonates. *J Bone Miner Res* 23:826–836.
101. Wessel JH, Dodson TB, Zavras AI. 2008 Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. *J Oral Maxillofac Surg* 66:625–631.
 102. Aguiar BD, Bohn SU, Cabrera Suarez MA, Aguiar MJ. 2007 Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. *Ann Oncol* 18:556–560.
 103. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. 2008 Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. *J Clin Oncol* 26:4634–4638.
 104. Tsao C, Darby I, Ebeling PR, et al. 2013 Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. *J Oral Maxillofac Surg* 71:1360–1366.
 105. Thumbigere-Math V, Tu L, Huckabay S, et al. 2012 A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. *Am J Clin Oncol* 35:386–392.
 106. Katz J, Gong Y, Salmasinia D, et al. 2011 Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. *Int J Oral Maxillofac Surg* 40:605–611.
 107. Montefusco V, Gay F, Spina F, et al. 2008 Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *Leuk Lymphoma* 49:2156–2162.
 108. Kunchur R, Goss AN. 2008 The oral health status of patients on oral bisphosphonates for osteoporosis. *Aust Dent J* 53:354–357.
 109. Mozzati M, Arata V, Gallesio G. 2012 Tooth extraction in patients on zoledronic acid therapy. *Oral Oncol* 48:817–821.
 110. Bonacina R, Mariani U, Villa F, Villa A. 2011 Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. *J Can Dent Assoc* 77:b147.
 111. Ferlito S, Puzzo S, Liardo C. 2011 Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. *J Oral Maxillofac Surg* 69:e1–e4.
 112. Vandone AM, Donadio M, Mozzati M, et al. 2012 Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. *Ann Oncol* 23:193–200.
 113. Lodi G, Sardella A, Salis A, et al. 2010 Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. *J Oral Maxillofac Surg* 68:107–110.
 114. Fehm T, Beck V, Banys M, et al. 2009 Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. *Gynecol Oncol* 112:605–609.
 115. Raje N, Woo SB, Hande K, et al. 2008 Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. *Clin Cancer Res* 14:2387–2395.
 116. Lehrer S, Montazem A, Ramanathan L, et al. 2009 Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. *J Oral Maxillofac Surg* 67:159–161.
 117. Hellstein JW, Adler RA, Edwards B, et al. 2011 Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. *J Am Dent Assoc* 142:1243–1251.
 118. Harper RP, Fung E. 2007 Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1–34)]. *J Oral Maxillofac Surg* 65:573–580.
 119. Bashutski JD, Eber RM, Kinney JS, et al. 2010 Teriparatide and osseous regeneration in the oral cavity. *N Engl J Med* 363:2396–2405.
 120. Giangregorio LM, Leslie WD, Lix LM, et al. 2012 FRAX underestimates fracture risk in patients with diabetes. *J Bone Miner Res* 27:301–308.
 121. Mucke T, Koschinski J, Deppe H, et al. 2011 Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. *J Cancer Res Clin Oncol* 137:907–913.
 122. Bedogni A, Saia G, Bettini G, et al. 2011 Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. *Oral Oncol* 47:420–424.
 123. Adornato MC, Morcos I, Rozanski J. 2007 The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. *J Am Dent Assoc* 138:971–977.
 124. Carlson ER, Basile JD. 2009 The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. *J Oral Maxillofac Surg* 67:85–95.
 125. Markose G, Mackenzie FR, Currie WJ, Hislop WS. 2009 Bisphosphonate osteonecrosis: a protocol for surgical management. *Br J Oral Maxillofac Surg* 47:294–297.
 126. Eckardt AM, Lemound J, Lindhorst D, et al. 2011 Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients: a challenging problem. *Anticancer Res* 31:2313–2318.
 127. Pautke C, Bauer F, Otto S, et al. 2011 Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. *J Oral Maxillofac Surg* 69:84–91.
 128. Wutzl A, Eisenmenger G, Hoffmann M, et al. 2006 Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. *Wien Klin Wochenschr* 118:473–478.
 129. Stockmann P, Vairaktaris E, Wehrhan F, et al. 2010 Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. *Support Care Cancer* 18:449–460.
 130. Wilde F, Heufelder M, Winter K, et al. 2011 The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 111:153–163.
 131. Saussez S, Javadian R, Hupin C, et al. 2009 Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. *Laryngoscope* 119:323–329.
 132. Yarom N, Yahalom R, Shoshani Y, et al. 2007 Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. *Osteoporos Int* 18:1363–1370.
 133. Mortensen M, Lawson W, Montazem A. 2007 Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. *Laryngoscope* 117:30–34.

134. Stanton DC, Balasanian E. 2009 Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. *J Oral Maxillofac Surg* 67:943–950.
135. Voss PJ, Joshi OJ, Kovalova-Muller A, et al. 2012 Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. *J Craniomaxillofac Surg* 40:719–725.
136. Williamson RA. 2010 Surgical management of bisphosphonate induced osteonecrosis of the jaws. *Int J Oral Maxillofac Surg* 39:251–255.
137. Diego R, D’Orto O, Pagani D, et al. 2007 Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 103:e1–e5.
138. Lescaille G, Coudert AE, Baaroun V, et al. 2013 Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis? *J Rheumatol* 40:781–786.
139. Alons K, Kuijpers SC, de Jong E, van Merkesteyn JP. 2009 Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 107:e1–e7.
140. Hoefert S, Eufinger H. 2011 Relevance of a prolonged pre-operative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. *J Oral Maxillofac Surg* 69:362–380.
141. Longobardi G, Boniello R, Gasparini G, et al. 2007 Surgical therapy for osteonecrotic lesions of the jaws in patients in therapy with bisphosphonates. *J Craniofac Surg* 18:1012–1017.
142. Biasotto M, Chiandussi S, Dore F, et al. 2006 Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws. *Acta Odontol Scand* 64:348–354.
143. Montebugnoli L, Felicetti L, Gissi DB, et al. 2007 Bisphosphonate-associated osteonecrosis can be controlled by nonsurgical management. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 104:473–477.
144. Moretti F, Pelliccioni GA, Montebugnoli L, Marchetti C. 2011 A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 112:777–782.
145. Estilo CL, Van Poznak CH, Williams T, et al. 2008 Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. *Oncologist* 13:911–920.
146. Ji X, Pushalkar S, Li Y, et al. 2012 Antibiotic effects on bacterial profile in osteonecrosis of the jaw. *Oral Dis* 18:85–95.
147. Epstein MS, Wicknick FW, Epstein JB, et al. 2010 Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 110:593–596.
148. Fortuna G, Ruoppo E, Pollio A, et al. 2012 Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. *J Oral Pathol Med* 41:222–228.
149. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. 2005 Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. *Cancer* 104:83–93.
150. Nicolatou-Galitis O, Papadopoulou E, Sarri T, et al. 2011 Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 112:195–202.
151. Vescovi P, Manfredi M, Merigo E, et al. 2010 Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). *Lasers Med Sci* 25:101–113.
152. Angiero F, Sannino C, Borloni R, et al. 2009 Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the Er:YAG laser. *Lasers Med Sci* 24:849–856.
153. Stubinger S, Dissmann JP, Pinho NC, et al. 2009 A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation. *Lasers Surg Med* 41:26–30.
154. Atalay B, Yalcin S, Emes Y, et al. 2011 Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? *Lasers Med Sci* 26:815–823.
155. Vescovi P, Merigo E, Manfredi M, et al. 2008 Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. *Photomed Laser Surg* 26:37–46.
156. Manfredi M, Merigo E, Guidotti R, et al. 2011 Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. *Int J Oral Maxillofac Surg* 40:277–284.
157. Martins MA, Martins MD, Lascala CA, et al. 2012 Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. *Oral Oncol* 48:79–84.
158. Romeo U, Galanakis A, Marias C, et al. 2011 Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results. *Photomed Laser Surg* 29:447–452.
159. Scoletta M, Arduino PG, Reggio L, et al. 2010 Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. *Photomed Laser Surg* 28:179–184.
160. Vescovi P. 2012 Bisphosphonates and osteonecrosis: an open matter. *Clin Cases Miner Bone Metab* 9:142–144.
161. Freiberger JJ, Padilla-Burgos R, McGraw T, et al. 2012 What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. *J Oral Maxillofac Surg* 70:1573–1583.
162. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. 2007 Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. *J Oral Maxillofac Surg* 65:1321–1327.
163. Andriani A, Petrucci MT, Caravita T, et al. 2012 Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom’s macroglobulinemia: a retrospective multicentric study. *Blood Cancer J* 2:e62.
164. Ripamonti CI, Cislighi E, Mariani L, Maniezzo M. 2011 Efficacy and safety of medical ozone (O₃) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study. *Oral Oncol* 47:185–190.

165. Agrillo A, Petrucci MT, Tedaldi M, et al. 2006 New therapeutic protocol in the treatment of avascular necrosis of the jaws. *J Craniofac Surg* 17:1080–1083.
166. Agrillo A, Ungari C, Filiaci F, et al. 2007 Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. *J Craniofac Surg* 18:1071–1075.
167. Ripamonti CI, Maniezzo M, Boldini S, et al. 2012 Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates—Preliminary data: medical ozone gas insufflation in treating ONJ lesions. *J Bone Oncol* 1:81–87.
168. Curi MM, Cossolin GS, Koga DH, et al. 2011 Bisphosphonate-related osteonecrosis of the jaws—an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. *J Oral Maxillofac Surg* 69:2465–2472.
169. Ciccio M, Herford AS, Juodzbaly G, Stoffella E. 2012 Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. *J Craniofac Surg* 23:784–788.
170. Khan AA, Sandor GK, Dore E, et al. 2008 Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. *J Rheumatol* 35:1391–1397.
171. Subramanian G, Cohen HV, Quek SY. 2011 A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 112:744–753.
172. Cella L, Oppici A, Arbasi M, et al. 2011 Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw. *Head Face Med* 7:16. doi:10.1186/1746-160X-7-16.
173. Vescovi P, Merigo E, Meleti M, et al. 2012 Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. *J Oral Pathol Med* 41:214–221.
174. Ngamphaiboon N, Frustino JL, Kossoff EB, et al. 2011 Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. *Clin Breast Cancer* 11:252–257.
175. Mozzati M, Gallesio G, Arata V, et al. 2012 Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. *Oral Oncol* 48:469–474.